Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Fuji
McKesson
Moodys
US Army
AstraZeneca
UBS
Healthtrust
Dow

Generated: May 26, 2018

DrugPatentWatch Database Preview

VIDEX EC Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Videx Ec patents expire, and when can generic versions of Videx Ec launch?

Videx Ec is a drug marketed by Bristol Myers Squibb and is included in one NDA.

The generic ingredient in VIDEX EC is didanosine. There are eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the didanosine profile page.
Drug patent expirations by year for VIDEX EC
Medical Subject Heading (MeSH) Categories for VIDEX EC
Synonyms for VIDEX EC
2 inverted exclamation mark ,3 inverted exclamation mark -Dideoxyinosine
2,3-dideoxyinosine
2', 3'-dideoxyinosine
2',3'-Dideoxyinosine
2',3'-Dideoxyinosine (AIDS Initiative)
2',3'-Dideoxyinosine (ddI)
2',3'-Dideoxyinosine & Granulocyte-macrophage colony-stimulating factor
2',3'-Dideoxyinosine & Interferon-.alpha.
2',3'-Dideoxyinosine & Interferon-alpha
2',3'-Dideoxyinosine & sCD4(soluble recombinant protein)
2',3'-Dideoxyinosine, >=98% (HPLC)
2',3'-dideoxyinosine, DDI, NSC 612049, Didanosine
2',3'-didesoxyinosin
2'3'-DIDEOXYINOSINE
2DI
3'-Azido-3'-deoxythymidine + 2',3'-Dideoxyinosine
3'-dideoxyinosine
655D056
69655-05-6
9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,9-dihydro-6H-purin-6-one
9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol
9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one
9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol
9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine
9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine
9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE
9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
9-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-6,9-DIHYDRO-1H-PURIN-6-ONE
9-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-6,9-DIHYDRO-3H-PURIN-6-ONE
9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one
9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-3H-purin-6-one
AB0014064
AB0069772
AB2000230
AC-12026
AC1L19ET
AJ-64234
AK-87600
AKOS015833088
AKOS015901454
AKOS015963259
AKOS026750545
AN-37869
ANW-35738
BC203896
BDBM50404252
Bio-0685
BMY 40900
BMY-40900
BRN 3619529
BXZVVICBKDXVGW-NKWVEPMBSA-N
C06953
CAS-69655-05-6
CCG-100947
CCG-220153
CCRIS 805
CHEBI:490877
CHEMBL1460
CJ-14439
CPD000058576
CS-2229
D00296
D06FDR
D0P6OM
D2I
D3066
DB-055315
DB00900
DDI
ddI & GM-CSF
ddI & IFN-.alpha.
DdI & IFN-alpha
ddI & sCD4(rsCD4)
ddI + d4T combination
DDI and rIFN.alpha.2
ddIno
Didanosina
Didanosina [INN-Spanish]
didanosine
Didanosine (JAN/USAN/INN)
Didanosine (Videx)
Didanosine [USAN:USP:INN:BAN]
Didanosine and Interferon-.alpha.-2
Didanosine for system suitability, European Pharmacopoeia (EP) Reference Standard
Didanosine, European Pharmacopoeia (EP) Reference Standard
Didanosine, United States Pharmacopeia (USP) Reference Standard
Didanosinum
Didanosinum [INN-Latin]
DIDEOXYINOSINE
Dideoxyinosine (DDI)
DRG-0016
DS-4152 & ddI
DSSTox_CID_2927
DSSTox_GSID_22927
DSSTox_RID_76791
DTXSID6022927
FT-0082664
GTPL4833
HE301567
HMS2051J11
HMS2089N20
HMS2095O08
HMS2232P22
HSDB 6548
HY-B0249
Hypoxanthine ddN
INO001
Inosine, 2',3'-dideoxy-
Inosine, 2',3'-dideoxy- & Recombinant Interferon-.alpha.-2
Inosine, 2',3'-dideoxy-& Recombinant Interferon-.alpha.-2
Intron A & Videx
J-700356
J10315
K166
K3GDH6OH08
KS-00000FVB
KS-1049
Lecithinized superoxide dismutase & Inosine, 2',3'-dideoxy-
Listera ovata agglutinin & 2',3'-Dideoxyinosine
LOA & ddI
MCULE-2844514954
MFCD00077728
MLS000759469
MLS001055350
MLS001424118
MLS002154216
MLS006011561
MolPort-002-507-371
MolPort-003-846-628
MolPort-006-167-656
NC00197
NCGC00090691-01
NCGC00090691-02
NCGC00090691-03
NCGC00159514-02
NCGC00159514-03
NCGC00159514-04
NCGC00164280-01
NCGC00188983-01
NCGC00254496-01
NCGC00259882-01
NSC 612049
NSC612049
NU000191
NU005155
PC-SOD+ddI
RTR-030612
S1702
SAM001246673
SC-58339
SCHEMBL3363
SMR000058576
SMR004703324
SRI-7013_07
SRI-7013-04
SRI-7013-05
Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxyinosine
Tox21_111732
Tox21_111732_1
Tox21_202333
Tox21_300575
TR-030612
UNII-K3GDH6OH08
Videx
Videx (TN)
Videx EC (TN)
Videx EC;Videx
Videx EC(TM)(slow-release capsules)
Videx(TM)
W-203551
Z1692482604
ZINC13597823

US Patents and Regulatory Information for VIDEX EC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb VIDEX EC didanosine CAPSULE, DELAYED REL PELLETS;ORAL 021183-001 Oct 31, 2000 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb VIDEX EC didanosine CAPSULE, DELAYED REL PELLETS;ORAL 021183-004 Oct 31, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb VIDEX EC didanosine CAPSULE, DELAYED REL PELLETS;ORAL 021183-002 Oct 31, 2000 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb VIDEX EC didanosine CAPSULE, DELAYED REL PELLETS;ORAL 021183-003 Oct 31, 2000 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for VIDEX EC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb VIDEX EC didanosine CAPSULE, DELAYED REL PELLETS;ORAL 021183-004 Oct 31, 2000 ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb VIDEX EC didanosine CAPSULE, DELAYED REL PELLETS;ORAL 021183-002 Oct 31, 2000 ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb VIDEX EC didanosine CAPSULE, DELAYED REL PELLETS;ORAL 021183-001 Oct 31, 2000 ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb VIDEX EC didanosine CAPSULE, DELAYED REL PELLETS;ORAL 021183-003 Oct 31, 2000 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VIDEX EC
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Delayed-release Capsules 200 mg, 250 mg and 400 mg ➤ Subscribe 2004-06-01

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Cipla
Queensland Health
Fish and Richardson
Cantor Fitzgerald
Argus Health
Farmers Insurance
Mallinckrodt
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.